

## **Zydus receives approval for Bromocriptine Mesylate Capsules**

---

Ahmedabad, 01 August 2008

Zydus Cadila has received an approval from the USFDA to market Bromocriptine Mesylate Capsules, 5 mg. The drug falls in the women's healthcare segment and is also used as an adjunct therapy in the CNS segment. The sales of Bromocriptine Mesylate Capsules as per NDC was estimated at USD 11.4 million in 2007.

The group now has 40 approvals and has so far filed 79 ANDAs since the commencement of filing process in FY 2003-04.

\*\*\*